PredictImmune initiates its PRECIOUS study to validate PredictSURE IBD
Category: #healthcare  By Mateen Dalal  Date: 2019-11-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

PredictImmune initiates its PRECIOUS study to validate PredictSURE IBD

The study would deliver crucial data that could help PredictImmune validate PredictSURE IBDTM in diverse patient populations.
 

PredictImmune has made its name by developing advanced tools for guiding treatment alternatives for diseases that are caused due to immune mediated diseases, like inflammatory bowel disease. Recently, the company made headlines when it announced the commencement of the PRECIOUS (Predicting Crohn’s and Colitis Outcomes in the United States) trial along with Crohn’s & Colitis Foundation.

For the record, the PRECIOUS trial is an observational, multi-center study of patients who suffer from active ulcerative colitis or Crohn’s disease and who are not treated with immunomodulators, biologics or systemic steroids.

Reports cite that the study would enroll a total of 200 patients from its 15 facilities present throughout the U.S. Moreover, patients enrolled by New York University/Bellevue will be the initial batch to enter the program. Also, after the collection of initial blood sample, the study would focus its resources on tracking patients’ progress for up to 12 months.

Patients from the study would be categorized at diagnosis into low-risk and high-risk cohorts using the company’s PredictSURE IBDTM biomarker. Apparently, PredictSURE IBDTM differentiates peoples based on the potential of suffering a serious disease course that would be categorized by the need for numerous escalations in therapy due to chronically active or frequently relapsing disease.

Speaking on the development, Paul Kinnon, CEO, PredictImmune, said that the company perceives this collaboration with Crohn’s & Colitis Foundation as a forward-looking step for both IBD and PredictImmune patients in the U.S.

Kinnon added that PredictImmune is thrilled to initiate the PRECIOUS trial, allowing them to extend its validation cohort and support the efficacy of the test in offering insights into the long-term course of the disease. Moreover, the study would propel both the firms one step closer to their vision of improving quality of life and disease outcomes for patients suffering from IBD.
 

Source Credit: https://www.predictimmune.com/predictimmune-and-the-crohns-colitis-foundation-announce-start-of-jointly-sponsored-study/

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

U.S. FDA approves FETROJA® (cefiderocol) for treatment of cUTI
U.S. FDA approves FETROJA® (cefiderocol) for treatment of cUTI
By Mateen Dalal

Shionogi & Co., Ltd., a Japan-based pharmaceutical company recently announced approval of drug c...

Disney stock soars as Disney+ reaches 10 million sign ups on day 1
Disney stock soars as Disney+ reaches 10 million sign ups on day 1
By Mateen Dalal

Reports confirm that Walt Disney Co shares climbed to a record high after the entertainment company ...

China’s Xpeng Motors secures $400m to expand electric car production
China’s Xpeng Motors secures $400m to expand electric car production
By Mateen Dalal

  Xpeng has already launched vehicles like G3 SUV and P7 sedan Xpeng and investors like Xia...